Ocugen OCGN
NASDAQ OCGN
$1.36 +0.01 (+0.74%)
At close: Sep 4, 2026 · 4:00 PM EDT

Ocugen (OCGN) Net Income towards Common Stockholders (2014 - 2026)

Ocugen's (OCGN) quarterly Net Income towards Common Stockholders came in at -$19.2 million in Q1 2026, down 24.93% YoY from -$25.5 million in Q1 2025, and down 24.93% on a QoQ basis from -$15.4 million in Q1 2025.

Analysis

Ocugen (OCGN) Net Income towards Common Stockholders (2014 - 2026) Analysis & Trends

Ocugen (OCGN) has 13 years of Net Income towards Common Stockholders data on file, last reported at -$19.2 million in Q1 2026.

  • Quarterly Net Income towards Common Stockholders fell 24.93% year-over-year to -$19.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$19.2 million (down 232.79% YoY) and the FY2024 annual result came in at -$44000.0, up 99.93% from the prior year.
  • Net Income towards Common Stockholders retreated to -$19.2 million in Q1 2026, from -$15.4 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $40.1 million in Q4 2024 to a low of -$63.1 million in Q4 2023.
  • A 5-year average of -$19.2 million and a median of -$21.9 million in 2022 frame the typical range for Net Income towards Common Stockholders.
  • Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders tumbled 187.52% — and 2024, when it surged 163.55%.
  • Tracing OCGN's Net Income towards Common Stockholders over 5 years: stood at -$21.9 million in 2022, then slumped by 187.52% to -$63.1 million in 2023, then surged by 163.55% to $40.1 million in 2024, then tumbled by 138.29% to -$15.4 million in 2025, then declined by 24.93% to -$19.2 million in 2026.
  • The last three Net Income towards Common Stockholders figures came in at -$19.2 million (Q1 2026), -$15.4 million (Q1 2025), and $40.1 million (Q4 2024), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 472.00 Mn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -782.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -644.37 Mn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 237.01 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 164.49 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 81.49 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -13.27 Mn
10 Ocugen 458.91 Mn 358.81 Mn - -24.88 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -24.88 Mn
Mar 31, 2026 -19.18 Mn
Dec 31, 2025 -17.71 Mn
Sep 30, 2025 -20.05 Mn
Jun 30, 2025 -14.74 Mn
Mar 31, 2025 -15.35 Mn
Dec 31, 2024 -13.88 Mn
Sep 30, 2024 -12.97 Mn
Jun 30, 2024 -10.29 Mn
Mar 31, 2024 -11.92 Mn
Dec 31, 2023 -10.97 Mn
Sep 30, 2023 -11.72 Mn
Jun 30, 2023 -23.07 Mn
Mar 31, 2023 -18.04 Mn
Dec 31, 2022 -21.94 Mn
Sep 30, 2022 -21.92 Mn
Jun 30, 2022 -21.58 Mn
Mar 31, 2022 -19.03 Mn
Dec 31, 2021 -14.58 Mn
Sep 30, 2021 -10.76 Mn